Optic Nerve Neoplasm malady

Categories: Cancer diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Optic Nerve Neoplasm

Aliases & Descriptions for Optic Nerve Neoplasm:

Name: Optic Nerve Neoplasm 12 14
Optic Nerve Neoplasms 42 69
Tumor of Second Cranial Nerve 12
Neoplasm of Optic Nerve 12
Tumour of Optic Nerve 12


External Ids:

Disease Ontology 12 DOID:3419
MeSH 42 D019574
NCIt 47 C4801
ICD10 33 C72.3
UMLS 69 C0524802

Summaries for Optic Nerve Neoplasm

MalaCards based summary : Optic Nerve Neoplasm, also known as optic nerve neoplasms, is related to watson syndrome and postgastrectomy syndrome. An important gene associated with Optic Nerve Neoplasm is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Neuroscience and Glioblastoma Multiforme. The drugs Ranibizumab and Carboplatin have been mentioned in the context of this disorder. Related phenotypes are Increased proliferation and behavior/neurological

Related Diseases for Optic Nerve Neoplasm

Diseases related to Optic Nerve Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
id Related Disease Score Top Affiliating Genes
1 watson syndrome 10.3 NF1 NF2
2 postgastrectomy syndrome 10.3 NF1 SYP
3 cervical adenoid cystic carcinoma 10.3 NF1 TP53
4 c-p angle neurinoma 10.2 NES NF1 NF2
5 adenofibroma 10.2 MAP2 NES SYP
6 dysgerminoma of ovary 10.2 NES NF2 SYP
7 infiltrating renal pelvis transitional cell carcinoma 10.2 ENO2 SYP
8 calcific tendinitis 10.2 MAP2 NES SYP
9 monckeberg arteriosclerosis 10.2 CDKN2A NF1 NF2
10 suppurative lymphadenitis 10.2 CDKN2A KRT5
11 thymus small cell carcinoma 10.2 ENO2 SYP
12 children's interstitial lung disease 10.2 MAP2 SYP
13 jejunal somatostatinoma 10.2 ENO2 NF1 NF2
14 pineal gland astrocytoma 10.2 NF1 TP53
15 skeletal-extraskeletal angiomatosis 10.2 ENO2 SYP
16 auricular cancer 10.2 FABP7 NES SYP
17 clear cell adenofibroma 10.2 CDKN2A TP53
18 autosomal recessive stickler syndrome 10.2 ENO2 MAP2 SYP
19 cavernous hemangioma of colon 10.2 ENO2 NF2
20 lacrimal gland adenoid cystic carcinoma 10.2 CDKN2A TP53
21 nephrogenic adenoma of urinary bladder 10.2 ENO2 NES SYP
22 prolactin producing pituitary tumor 10.2 ENO2 KRT5 SYP
23 vaginal endometrial stromal sarcoma 10.2 CDKN2A KRT5 NF2
24 superior vena cava syndrome 10.2 ENO2 NES SYP
25 zollinger-ellison syndrome 10.2 ENO2 NF1 SYP
26 pediculus humanus corporis infestation 10.2 ENO2 NES SYP
27 brain stem astrocytic neoplasm 10.2 MAP2 SYP TP53
28 anal squamous cell carcinoma 10.2 ENO2 KRT5 SYP
29 bronchitis 10.2 NF2 TP53
30 paternal uniparental disomy of chromosome 1 10.2 NES SYP TP53
31 pericardium leiomyoma 10.2 CDKN2A TP53
32 diphtheria 10.1 ENO2 MIB1 NF1 NF2
33 epidural abscess 10.1 ENO2 MIB1 NF1 NF2
34 glomus tumor 10.1 ENO2 SYP
35 pathologic nystagmus 10.1 CDKN2A NF1 NF2 SYP
36 vulva adenocarcinoma 10.1 KRT5 SYP TP53
37 extragonadal germ cell cancer 10.1 NES SYP TP53
38 immunodeficiency due to a classical component pathway complement deficiency 10.1 CDKN2A NF2
39 benign ependymoma 10.1 KRT5 SYP TP53
40 paraphimosis 10.1 CDKN2A SYP TP53
41 thymus squamous cell carcinoma 10.1 CDKN2A SYP TP53
42 perineural angioma 10.1 ENO2 SYP TP53
43 blood group incompatibility 10.1 ENO2 SYP TP53
44 pacinian tumor 10.1 CDKN2A SYP TP53
45 combined thymoma 10.1 KRT5 SYP TP53
46 spinal cord oligodendroglioma 10.1 CDKN2A KRT5 TP53
47 growth retardation hydrocephaly lung hypoplasia 10.1 ENO2 SYP TP53
48 plasmodium ovale malaria 10.1 CDKN2A KRT5 TP53
49 childhood central nervous system primitive neuroectodermal neoplasm 10.1 ENO2 SYP TP53
50 multiple chemical sensitivity 10.1 ENO2 SYP TP53

Graphical network of the top 20 diseases related to Optic Nerve Neoplasm:

Diseases related to Optic Nerve Neoplasm

Symptoms & Phenotypes for Optic Nerve Neoplasm

GenomeRNAi Phenotypes related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

MGI Mouse Phenotypes related to Optic Nerve Neoplasm:

id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 ACE CDKN2A ENO2 FABP7 KRT5 LOX
2 growth/size/body region MP:0005378 10.15 ACE CDKN2A ENO2 H2AFX KRT5 MAP2
3 homeostasis/metabolism MP:0005376 10.1 MIB1 MTO1 NF1 NF2 OPTN SOX3
4 mortality/aging MP:0010768 10.07 TP53 ACE CDKN2A H2AFX KRT5 LOX
5 endocrine/exocrine gland MP:0005379 10.06 ACE CDKN2A H2AFX MAP2 MIB1 NF1
6 craniofacial MP:0005382 9.98 TP53 ENO2 KRT5 MIB1 NF1 NF2
7 nervous system MP:0003631 9.65 CDKN2A ENO2 FABP7 MAP2 MIB1 NF1
8 neoplasm MP:0002006 9.63 TP53 ACE CDKN2A H2AFX NF1 NF2
9 no phenotypic analysis MP:0003012 9.17 CDKN2A FABP7 KRT5 MIB1 OPTN SOX3

Drugs & Therapeutics for Optic Nerve Neoplasm

Drugs for Optic Nerve Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
Ephedrine Approved Phase 4 299-42-3 9294
Pseudoephedrine Approved Phase 4 90-82-4 7028
Nicotine Approved Phase 4 54-11-5 942 89594
14 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antiviral Agents Phase 4,Phase 2,Phase 1
21 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Hormones Phase 4,Phase 3,Phase 2,Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
26 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
27 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
30 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 triamcinolone acetonide Phase 4,Phase 2,Phase 3
33 Triamcinolone diacetate Phase 4,Phase 2,Phase 3
34 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3
35 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
36 Interferon-beta Phase 4,Phase 2
37 interferons Phase 4,Phase 2
38 Antifungal Agents Phase 4,Phase 2,Phase 1
39 Cytochrome P-450 CYP3A Inhibitors Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
41 Hydroxyitraconazole Phase 4
42 Steroid Synthesis Inhibitors Phase 4
43 Antihypertensive Agents Phase 4
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
46 Adrenergic Agents Phase 4
47 Adrenergic Agonists Phase 4
48 Adrenergic alpha-2 Receptor Agonists Phase 4
49 Adrenergic alpha-Agonists Phase 4
50 Brimonidine Tartrate Phase 4 70359-46-5

Interventional clinical trials:

(show top 50) (show all 370)
id Name Status NCT ID Phase
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
2 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
3 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
4 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
5 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4
6 Preoperative Brimonidine on IOP of Patients Undergoing RALP Recruiting NCT02818816 Phase 4
7 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
8 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
9 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
10 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3
11 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3
12 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer Completed NCT00390806 Phase 3
13 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed NCT00079417 Phase 3
14 Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma Completed NCT00072384 Phase 3
15 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
16 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3
17 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Completed NCT00033293 Phase 3
18 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma Completed NCT00335738 Phase 3
19 Evaluation of Pigmented Skin Lesions With MelaFind(R) System Completed NCT00434057 Phase 3
20 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3
21 Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3
22 Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma Recruiting NCT02739555 Phase 3
23 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Recruiting NCT01892345 Phase 3
24 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Recruiting NCT02073279 Phase 3
25 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3
26 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
27 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
28 Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Recruiting NCT01906814 Phase 3
29 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting NCT00186888 Phase 3
30 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3
31 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
32 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3
33 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
34 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3
35 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3
36 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3
37 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
38 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3
39 Quadrant Versus Superficial Parotidectomy Withdrawn NCT01607866 Phase 2, Phase 3
40 Whole-Brain Radiotherapy (WBRT) Versus WBRT and Integrated Boost Using Helical Tomotherapy for Multiple Brain Metastases Unknown status NCT00876759 Phase 2
41 Randomized Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial. Unknown status NCT01795300 Phase 1, Phase 2
42 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2
43 Study of Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2
44 Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Unknown status NCT00179920 Phase 2
45 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2
46 Pain Relief - Tramadol Versus Ibuprofen Unknown status NCT00111046 Phase 1, Phase 2
47 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2
48 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Unknown status NCT01034787 Phase 2
49 Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Unknown status NCT00202930 Phase 2
50 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2

Search NIH Clinical Center for Optic Nerve Neoplasm

Cochrane evidence based reviews: optic nerve neoplasms

Genetic Tests for Optic Nerve Neoplasm

Anatomical Context for Optic Nerve Neoplasm

Publications for Optic Nerve Neoplasm

Variations for Optic Nerve Neoplasm

Expression for Optic Nerve Neoplasm

Search GEO for disease gene expression data for Optic Nerve Neoplasm.

Pathways for Optic Nerve Neoplasm

Pathways related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.61 ENO2 FABP7 MAP2 NF1 NF2 SYP
2 11.5 CDKN2A NF1 NF2 TP53
3 11.16 FABP7 MAP2 NES SYP

GO Terms for Optic Nerve Neoplasm

Biological processes related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of protein kinase activity GO:0006469 9.58 CDKN2A NF1 NF2
2 regulation of long-term neuronal synaptic plasticity GO:0048169 9.37 NF1 SYP
3 negative regulation of cell proliferation GO:0008285 9.35 CDKN2A FABP7 NF1 NF2 TP53
4 Ras protein signal transduction GO:0007265 9.33 CDKN2A NF1 TP53
5 negative regulation of MAPK cascade GO:0043409 9.32 NF1 NF2
6 replicative senescence GO:0090399 9.26 CDKN2A TP53
7 negative regulation of cell-matrix adhesion GO:0001953 8.8 CDKN2A NF1 NF2

Sources for Optic Nerve Neoplasm

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....